Hammold Pharmaceuticals Inc.
IPO Prospectus
November 1, 2018
Hammold Pharmaceuticals Inc. (“Hammold” or the “Company”) is pleased to announce the Initial Public Offering (“IPO”) of its common shares. The Company seeks to raise $75 million from this offering.
Overview
Founded in 2009, Hammold is headquartered in London, UK and operates globally. The Company develops and commercializes innovative therapies for the treatment of oncologic, neurologic, and metabolic diseases. Combining its in-house scientific team and network of Global Research Centers, the Company has created a foundation of proprietary drug development portfolio in several therapeutic areas.
In the past three years, Hammold has become the leading independent producer of generic biologic products with a presence in over 30 countries. As a result of the Company’s success, sales have grown from $1.5 billion in 2016 to an estimated $3 billion in 2018.
Objectives
Hammold’s primary objective for the IPO is to raise capital for the expansion of its sales, marketing and research and development activities. Specifically, the funds will be used to hire and train additional personnel, strengthen the existing pipeline of potential products, as well as purchase equipment and other necessary resources as needed.
In addition, Hammold intends to use the proceeds to expand its global footprint by establishing new research centers, subsidiaries and other operations in key international markets.
Company Strengths
Hammold’s core strength is the innovation of its development pipeline, which the Company believes will lead to the launch of numerous new products over the next few years. In addition, the management team’s deep understanding of the drug development process is applicable across multiple therapeutic areas.
In terms of manufacturing, the Company has achieved significant scale in the commercialization of its biologic products. The Company has achieved efficiencies in the production of these products as compared to competitors.
Finally, the revenue from recently launched products is reinforcing Hammold’s reputation for developing and commercializing the most advanced therapies. With a strong presence in international markets and alliances with key partners, Hammold is well positioned for continued insights and market penetration.
Management Team
Hammold’s leadership team is composed of seasoned professionals who have extensive experience in corporate finance, business development and pharma sales and marketing. The team is led by John Jacobs, CEO, who brings 25 years of pharmaceutical development and commercialization experience to the Company.
Investment Highlights
Hammold’s unique positioning in a growing global market has allowed the Company to capitalize on significant opportunities to diversify and expand its product portfolios. Moreover, Hammold’s successful track record of launching innovative new products has further solidified its competitive standing within the therapeutic market.
Conclusion
Hammold Pharmaceuticals Inc. has a strong opportunity to become a leader in the development and commercialization of innovative new treatments. The offering of common shares provides investors with a chance to capitalize on the Company’s current momentum and invest in its continued growth.
